Patent intelligence · US
US 10793564
Amino acid compounds and methods of use
Amino acid compounds and methods of use
Patent details — US 10793564
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 6, 2020
- Expiration
- Oct 1, 2040
- Applicant
- Pliant Therapeutics, Inc.
- Claims
- 69
- CPC classes
- A61P, A61P43/00
Quick answer
US 10793564 (Amino acid compounds and methods of use) is held by Pliant Therapeutics, Inc.. Status: granted. Granted Oct 6, 2020. Expires Oct 1, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Pliant Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 69
- CPC classes
- A61P, A61P43/00
More from Pliant Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12390463
Dosage forms and regimens for amino acid compounds
granted -
US 12134642
Antibodies binding to α7β1 integrin antibodies and compositions thereof
granted -
US 11952376
Substituted amino acids as integrin inhibitors
granted -
US 11858931
Amino acid compounds with unbranched linkers and methods of use
granted -
US 11673887
N-acyl amino acid compounds and methods of use
granted -
US 11634418
Amino acid compounds and methods of use
granted -
US 11560376
Amino acid compounds and methods of use
granted -
US 11419869
Dosage forms and regimens for amino acid compounds
granted
Frequently asked questions
What is US patent 10793564?
US 10793564 (Amino acid compounds and methods of use) is held by Pliant Therapeutics, Inc.. Status: granted. Granted Oct 6, 2020. Expires Oct 1, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10793564?
Pliant Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 13 pharmaceutical patents for this assignee.
When does US 10793564 expire?
Our index shows an expiration date of Oct 1, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.